Avid Bioservices Inc (CDMO)

[biopharm]

Why did Steve Demattos leave Peregrine Pharmaceuticals? Did we ever see his deposition taken in regards to the sabotage at CSM where all court records are sealed? Well now he is working at Xencor ....the same Xencor as John Stafford where it seemed he had to exit Xencor before jumping on with Ronin Hedge Group....hmmmm

Have the new BODs gained access to all depositions so they can make a fiduciary duty decision on value of PS Targeting and a value they would likely realize is being restricted and hidden....

No public announcement from the new BODs in regards to Steve Demattos departure of Pergrine Pharmaceuticals ? No excuse because the new BODs CAN NOT use the excuse that what happened in the past has no bearing now because it certainly matters. It matters because who knows what was concealed in the depositions or what trade secrets were use with Steve Demattos over at Xencor now ....the same Xencor and here John Stafford has left their BOD but buying up alot of Xencor stock this past year.....which all coincides with Stafford / Steve White with Ronin Hedge Group as it seems they are trying to conceal the true value of PS Targeting IP ...

Steve Demattos listed as contact for Xencor trial
Contact: Steve DeMattos, BS 858-480-3892 [e-mail]
https://clinicaltrials.gov/ct2/show/NCT02725515

Is this Xencor Xmab5871 infringing upon PS Targeting IP rights? I say YES and this is why we must ask the new BODs to make damn sure they protect the IP assets and KNOWING the details of Steve Demattos departure, his confidentiality agreement, his deposition in relation to the sabotage by CSM who had CEO Gerald Finken and his sidekick Jeanette Bleecker that we know already admitted swapping and sabotaging the Peregrine trial....is critical to realizing the true value of the PS Targeting IP at Peregrine, now called Avid Bioservices.

Ask the new BODs why they are not getting all this information and making it known to the public and all shareholders.....as they can't keep it a secret when they get requests via certified letters.

XmAb5871 is a first-in-class monoclonal antibody that targets CD19 with its variable domain and uses the XmAb immune inhibitory Fc domain to target Fc?RIIb, a receptor that inhibits B cell function. XmAb5871 is the first drug candidate to our knowledge that targets Fc?RIIb inhibition.

Yes, Xencor to their knowledge MAY now know PS Targeting rights are being infringed upon....

If everyone does not resend certified letters and question EVERYTHING ....then we will see breadcrumb nothing in return for the sale or license of the PS Targeting platform

Seek the answers

Now